Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal conjugate vaccine, ACWY-CRM
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal conjugate vaccine, ACWY-CRM is a quadrivalent glycoconjugate vaccine designed for the prevention of invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W, and Y. It contains purified polysaccharides from these serogroups, each conjugated to the non-toxic diphtheria cross-reacting material 197 (CRM197) protein, enhancing immunogenicity by stimulating T-cell dependent immunity. There are two main presentations: the original two-vial formulation (MenA lyophilized + MenC/W/Y liquid, requiring reconstitution before injection) and a newer, single-vial fully liquid formulation, developed to improve ease of use and reduce the risk of administration errors. The vaccine is administered as a single 0.5 mL intramuscular dose and has demonstrated robust immunogenicity, safety, and non-inferior efficacy compared to traditional presentations in phase 2b clinical studies[1][4].
- Brand names
- Menveo
- Other names
- meningococcal ACWY conjugate vaccinequadrivalent meningococcal conjugate vaccineMenACWY liquidMenACWY licensed
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)CRM197 (Diphtheria toxin CRM197 mutant)HBEGF (Heparin-binding EGF-like growth factor)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal conjugate vaccine, ACWY-CRM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal conjugate vaccine, ACWY-CRM.